Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here
Acquired Thrombotic Thrombocytopenic Purpura (aTTP) is a rare blood disorder that, when left untreated leads to a 95% morbidity rate. This case study provides an overview of a recent Phase III study, we partnered with a progressive sponsor company to assist in finding a better solution for patients suffering with aTTP.
Blood disorders and other hematological conditions are becoming increasingly frequent – and with them, the research. From relatively common disorders such as anemia to blood cancers and platelet disorders, hematology research is experiencing new breakthroughs. Choose a Hematology CRO that has the knowledge and experience to execute complex studies with today’s best supportive technologies.
We have run multiple studies in the three main blood cancers; leukemia, lymphoma and myeloma. Pharm-Olam is focused on early phase oncology and maintains therapeutically aligned staff for ready to initiate your next oncology clinical trials. To learn more about our extensive Oncology CRO expertise, click below.
Pharm-Olam has vast hematology expertise, having supported idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia among numerous others. Our team goes the distance for patients in need. To learn more about our Autoimmune CRO Services, click below.
At Pharm-Olam, we understand hematological issues including rare conditions like Myelofibrosis. We have supported numerous hematological rare disease clinical trials which lead to marketed products for patients in need. To learn more about our Rare Disease CRO Services, click below.
